Januvia, Galvus, Onglyza and Trajenta vie for market share in Korea

Published: 2011-11-17 06:59:00

Updated: 2011-11-17 06:59:00

Multinational pharmaceutical companies will step up their marketing in the domestic dipeptidyl peptidase-IV (DPP-IV) inhibitors market dominated by Merck’s Januvia (sitagliptin) and Novartis’s Galvus (vildagliptin), which is expected to become more competitive than ever late this year, according ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK